APOA4

APOA4 is a multifunctional apolipoprotein that links lipid transport to metabolic and immune regulation across the liver, vasculature, and adipose tissue (PMID:31462513, PMID:34168225, PMID:36426356). As a lipid carrier it binds and transports the bioactive lipid sphingosine 1-phosphate, activating S1P receptors and supporting vascular endothelial barrier function in place of ApoM and albumin (PMID:31462513), while in its lipid-free versus lipid-bound states it exhibits distinct multimerization and weaker LCAT activation and lipid-binding behavior than ApoA-I (PMID:25997739). At the cell surface APOA4 engages defined receptors to drive metabolic signaling: it binds LRP1 in adipocytes to stimulate glucose uptake through PI3K/AKT activation (PMID:34168225) and interacts directly with CD300LG at the microvascular endothelium to promote clearance of triglyceride-rich lipoproteins [PMID:bio_10.1101_2025.08.08.669356]. APOA4 also functions as a regulator of inflammation, suppressing hepatic innate immune cell activation in NAFLD (PMID:36426356) and acting through nuclear receptors NR4A1 and NR1D1 to transcriptionally induce the anti-inflammatory gene SERPINA3 (PMID:28412351). Its own hepatic expression is controlled by HGF/c-Met signaling (PMID:33925510) and a reciprocal regulatory loop with PCSK9 in cholesterol metabolism (PMID:40206272). Pathogenic missense mutations p.L66V and p.D33N render APOA4 itself the predominant amyloid constituent in autosomal dominant medullary amyloidosis with chronic kidney disease (PMID:38096951).

1. 1986 Medium

   Establishing the gene's intron/exon architecture answered whether APOA4 is evolutionarily related to other apolipoproteins, placing it in a shared ancestral lineage with APOA1 and APOC3.

   Evidence Gene isolation, restriction mapping, and intron/exon structure analysis of the human APOA4 locus

   PMID:3095836

   Open questions at the time

   • No functional or mechanistic role assigned to the encoded protein
   • Structure-function consequences of intron loss not addressed
2. 2017 Medium

   Identifying NR4A1/NR1D1-mediated induction of SERPINA3 provided a transcriptional mechanism for how APOA4 exerts anti-inflammatory effects in hepatocytes.

   Evidence ChIP, luciferase reporter, and NR4A1/NR1D1 siRNA in mouse hepatocytes with in vivo/in vitro expression analysis

   PMID:28412351

   Open questions at the time

   • How extracellular APOA4 signals to nuclear receptors is unresolved
   • Single laboratory, mouse hepatocyte system
3. 2019 High

   Demonstrating direct S1P binding and receptor activation established APOA4 as a bona fide S1P chaperone capable of supporting endothelial barrier function, extending its role beyond classical lipid transport.

   Evidence Recombinant protein S1P binding, S1P receptor activation, endothelial barrier assays, and ApoM/albumin double-knockout mice

   PMID:31462513

   Open questions at the time

   • Physiological contribution relative to ApoM in normal animals not quantified
   • S1P-binding residues not mapped
4. 2021 High

   Identifying LRP1 as a cognate receptor explained how APOA4 triggers intracellular glucose-uptake signaling in adipose tissue.

   Evidence Co-IP/MS, co-localization, LRP1 siRNA knockdown, glucose uptake and PI3K/AKT readouts in 3T3-L1 adipocytes

   PMID:34168225

   Open questions at the time

   • In vivo confirmation of LRP1-dependent glucose uptake not established
   • Binding interface and stoichiometry undefined
5. 2021 Medium

   Linking hepatic APOA4 induction to HGF/c-Met signaling identified an upstream growth-factor pathway controlling APOA4 expression in liver injury.

   Evidence rh-HGF administration in mice and primary human hepatocytes with c-Met inhibitor blockade and serum APOA4 measurement

   PMID:33925510

   Open questions at the time

   • Transcription factors downstream of c-Met driving APOA4 not identified
   • Functional consequence of HGF-induced APOA4 unclear
6. 2022 Medium

   Single-cell profiling of ApoA4-deficient livers resolved which immune cell populations APOA4 restrains, defining its suppressive role over inflammatory macrophages and granulocytes in NAFLD.

   Evidence scRNA-seq of liver immune cells from WT and ApoA4-KO mice on high-fat diet with immunostaining and qRT-PCR validation

   PMID:36426356

   Open questions at the time

   • Direct versus indirect action of APOA4 on immune cells not separated
   • Receptor mediating immune suppression not identified
7. 2023 High

   Mapping p.L66V and p.D33N to medullary amyloidosis established APOA4 itself as a causative amyloidogenic protein in an inherited kidney disease.

   Evidence Whole genome sequencing, clinical genetics across five families, and mass spectrometry of amyloid in kidney biopsies

   PMID:38096951

   Open questions at the time

   • Mechanism by which mutations promote fibrillization not experimentally demonstrated
   • Why deposition is medullary/kidney-specific unexplained
8. 2025 Medium

   Defining the reciprocal PCSK9–APOA4 loop showed APOA4 participates in a feedback circuit governing hepatocyte cholesterol metabolism.

   Evidence siRNA/overexpression in AML12 hepatocytes, RNA-seq, ELISA, and a murine TMAO-induced cholelithiasis model

   PMID:40206272

   Open questions at the time

   • Molecular intermediary of the reciprocal regulation unknown
   • Whether regulation is transcriptional or post-translational unresolved
9. 2025 Medium

   Identifying a direct APOA4–CD300LG interaction provided an endothelial receptor mechanism for postprandial triglyceride-rich lipoprotein clearance.

   Evidence Direct protein interaction assay, CD300LG-deficient mice, human genetics, and postprandial lipid clearance (preprint)

   PMID:bio_10.1101_2025.08.08.669356

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • Binding interface and downstream uptake machinery undefined
10. 2026 Medium

    Demonstrating APOA4 chondroprotection via Wnt/β-catenin suppression extended its anti-inflammatory and tissue-protective role to cartilage.

    Evidence Recombinant APOA4, siRNA, overexpression in C28/I2 chondrocytes with IL-1β model and Wnt3a rescue

    PMID:42147793

    Open questions at the time

    • Receptor mediating chondrocyte effects not identified
    • In vivo cartilage relevance not tested

• How APOA4's distinct receptor engagements (LRP1, CD300LG, S1P receptors) and transcriptional circuits are coordinated into a unified physiological program, and how missense mutations convert it into an amyloidogenic protein, remain open.
• No structural model linking lipid/receptor binding to amyloid propensity
• Tissue-specific receptor usage not integrated
• Causal in vivo hierarchy among the regulatory loops unestablished